Skip to content
Screener

Total Equity at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$22.32B+28.0%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$84.97B+8.3%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
$3.41B+34.4%
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
$1.31B+58.9%
AbbVie logo
AbbVieABBV
-$6.66B-569%
LBR
LB Pharmaceuticals IncLBRX
$378.69M+481%

Other financials

Income statement

See full
Operating income-$64.5M-174%
Net income-$60.7M-172%
EPS (diluted)-$1.34+95.4%

Balance sheet

See full
Cash & equivalents$55.7M
Total debt$5.6M
Total assets$418.8M

Cash flow

See full
Operating cash flow-$51.2M-100%
CapEx$24.0K
Free cash flow-$51.2M

Valuation

See full
Market cap$602.19M-13.2%
Enterprise value$552.07M

Returns & leverage

See full
Return on equity-216.8%
Debt / equity
Current ratio22.9×

Where this comes from

Reported directly by MapLight Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The source filing: MapLight Therapeutics, Inc.’s 10-Q, filed May 14, 2026.

Filed
May 14, 2026, 4:25 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-224129
Line itemMarch 31, 2026December 31, 2025
Stockholders' equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized at March 31, 2026 and December 31, 2025; no shares issued and outstanding at March 31, 2026 and December 31, 2025
Common stock, $0.0001 par value per share; 500,000,000 shares authorized at March 31, 2026 and December 31, 2025; 45,208,922 and 44,024,088 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively55
Additional paid-in-capital821,900819,115
Accumulated other comprehensive loss(883)(228)
Accumulated deficit(421,188)(360,520)
Total stockholders' equity399,834458,372
Total liabilities and stockholders' equity$418,788$479,512

Item 1. Financial Statements.

FAQ

What is MapLight Therapeutics, Inc.'s total equity?
MapLight Therapeutics, Inc. (MPLT) reported total equity of $399.83M in Q1 2026.
How has MapLight Therapeutics, Inc.'s total equity changed year-over-year?
MapLight Therapeutics, Inc.'s total equity increased by 285.3% year-over-year, from -$215.83M to $399.83M.
What is the long-term trend for MapLight Therapeutics, Inc.'s total equity?
Over 2 years (2023 to 2025), MapLight Therapeutics, Inc.'s total equity has grown at a 97.4% compound annual growth rate (CAGR), from -$117.59M to $458.37M.
What does total equity mean?
Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.

Ask your AI about MapLight Therapeutics, Inc.'s total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude